Company: FTII
Filing Date: 2025-02-14
Form Type: S-4
Source: 0001493152-25-006997
Chunk: 436

Company: FutureTech II Acquisition Corp.
Filing Date: 2025-02-14
Form: S-4
Chunk 436
---
, Cerevast entered into the Fourth Amendment to the C&E Agreement to amend the closing condition of an approved deSPAC transaction to a valuation of not less than $75 million and modify the allocation of the transaction consideration among the Targets and FutureTech Capital.

Business Combination

Please see the section titled “ Proposal No. 1 — The Business Combination Proposal” for more information about the Merger Agreement.

| 239 |

Components of Operating Results

Revenue

Since inception, we have not generated any revenue and do not expect to generate any revenue from the sale of products in the near future. If our development efforts for our product candidates are successful and result in regulatory approval, or if we entered into collaboration and license agreements with third parties, we may generate revenue from the combination of product sales or payments from collaboration or license agreements.

Research and Development Expenses

Research and development expenses consist of costs incurred in the development of our product candidates and primarily include:

● expenses in connection with the development of our pipeline products;

● costs of pre-clinical activities and clinical trials;

● costs of raw materials, as well as manufacturing costs of our materials, used in clinical trials and other development efforts;

● costs for consulting services;

● license fees and patent expenses;

● salaries, stock-based compensation, benefits and travel expenses of employees engaged in research and development activities;

● facility expense, depreciation expense related to lab equipment; and

● costs of regulatory submissions and reviews.

We expense research and development costs as incurred.

Research and development costs are essential to our business model. We expect that our research and development expenses will continue to increase for the foreseeable future as we continue clinical development or our product candidates. As products enter later stages of clinical development, they will generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials. We expect to fund our research and development expenses from our current cash and cash equivalents and any future equity or debt financings, or other capital sources, including potential collaborations with other companies or strategic transactions.

General and Administrative Expenses

General and administrative expenses consist primarily of salaries, stock-based compensation and related costs for our employees in administrative, executive and finance functions. General and administrative expenses also include professional fees for legal, accounting, tax and consulting services, insurance, office and travel expenses.

We expect that our general and administrative expenses will increase in the future as we increase our general and administrative headcount to support our continued research and development and initial commercialization of our product candidates.